Guy Bruno, Barban Veronique, Mantel Nathalie, Aguirre Marion, Gulia Sandrine, Pontvianne Jeremy, Jourdier Therese-Marie, Ramirez Laurence, Gregoire Veronique, Charnay Christophe, Burdin Nicolas, Dumas Rafaele, Lang Jean
Research and Discovery Departments, Sanofi Pasteur, Marcy l'Etoile, France.
Am J Trop Med Hyg. 2009 Feb;80(2):302-11.
Interferences between different antigens in the same vaccine formulation have been reported for some vaccines (e.g., polio vaccines, live attenuated dengue vaccine candidates). We examined interferences between the four serotypes of ChimeriVax dengue vaccines (CYDs) in a monkey model when present within a tetravalent formulation in equal concentrations (TV-5555). Immunoassays of vaccinated non-human primates showed that serotype 4 (DEN-4), and to a lesser extent, DEN-1 were dominant in terms of neutralizing antibody levels. Parameters that affected the interferences were identified, including 1) the simultaneous administration of two complementary bivalent vaccines at separate anatomical sites drained by different lymph nodes; 2) the sequential administration of two complementary bivalent vaccines; 3) the establishment of heterologous flavivirus pre-immunity before subsequent tetravalent immunization; 4) the adaptation of formulations by decreasing the dose of the immunodominant serotype; and 5) the administration of a 1-year booster. The applicability of these data to human responses is discussed.
对于某些疫苗(如脊髓灰质炎疫苗、减毒活登革疫苗候选株),已报道了同一疫苗配方中不同抗原之间的干扰情况。我们在猴模型中研究了四价配方(TV-5555)中浓度相等的四种血清型的嵌合登革疫苗(CYD)之间的干扰。对接种疫苗的非人灵长类动物进行的免疫分析表明,血清型4(DEN-4),以及程度稍轻的DEN-1,在中和抗体水平方面占主导地位。确定了影响干扰的参数,包括:1)在由不同淋巴结引流的不同解剖部位同时接种两种互补的二价疫苗;2)依次接种两种互补的二价疫苗;3)在后续四价免疫之前建立异源黄病毒预免疫;4)通过降低免疫显性血清型的剂量来调整配方;5)接种1年加强针。讨论了这些数据对人类反应的适用性。